scholarly journals Correctly measuring drug development risk: a public policy imperative

2011 ◽  
Vol 11 (1) ◽  
pp. 1-3 ◽  
Author(s):  
John A Vernon ◽  
Joseph H Golec
Keyword(s):  
Public Policy ◽  
Drug Development ◽  
Development Risk

Drug development risk in HIV-1 clinical trials: the effect of drug class

2011 ◽  
Vol 2 (4) ◽  
pp. 211-216 ◽  
Author(s):  
Brendan J.W. Osborne ◽  
Rupert Kaul ◽  
Jayson L. Parker
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Drug Class ◽  
Development Risk ◽  
Hiv 1

Paternalism and Public Health

2017 ◽  
Author(s):  
Jessica Flanigan
Keyword(s):  
Public Health ◽  
Public Policy ◽  
Drug Development ◽  
New Drugs ◽  
Health Policies ◽  
Clinical Context ◽  
Public Health Policies ◽  
Patients Rights ◽  
Medical Paternalism ◽  
New Drug Development

Since medical paternalism is wrong in the clinical context, it should be rejected in public policy as well. But even if paternalistic public health policies were permissible, it is not clear that prohibitive pharmaceutical regulations are necessary to promote public health. Prohibitions could undermine health in some cases, for example, if prescription requirements make patients more deferential to physicians and tolerant of medical risks. Premarket testing requirements cause people to suffer and die waiting for new drugs to get approved, and they discourage new drug development. This is not to say that regulation serves no purpose. Pharmaceutical regulators provide a valuable pubic good by overseeing testing for new drugs and by certifying drugs that they deem generally safe and effective. But the benefits of regulation do not require that the regulations be prohibitive, and prohibitive regulations not only violate patients’ rights, they may also cost lives.

Drug development risk and the cost of capital

2012 ◽  
Vol 11 (5) ◽  
pp. 347-348 ◽  
Author(s):  
Aris I. Baras ◽  
Alex S. Baras ◽  
Kevin A. Schulman
Keyword(s):  
Drug Development ◽  
Cost Of Capital ◽  
The Cost ◽  
Development Risk

scholarly journals A Machine Learning approach for assessing drug development risk

2020 ◽  
Author(s):  
Vangelis Vergetis ◽  
Gerasimos Liaropoulos ◽  
Maria Georganaki ◽  
Andreas Dimakakos ◽  
Dimitrios Skaltsas ◽  
...  
Keyword(s):  
Machine Learning ◽  
Clinical Trials ◽  
Drug Development ◽  
Unbiased Estimate ◽  
Regulatory Approval ◽  
Learning Approach ◽  
Allocation Of Resources ◽  
Machine Learning Approach ◽  
Development Risk

ABSTRACTCharacterizing drug development risk – the probability that a drug will eventually receive regulatory approval – has been notoriously hard given the complexities of drug biology and clinical trials. This often leads to an inefficient allocation of resources, and an overall reduction in R&D productivity. We propose a Machine Learning (ML) approach that provides a more accurate and unbiased estimate of drug development risk than traditional models.

Assessing drug development risk using Big Data and Machine Learning

2020 ◽  
pp. canres.0866.2020
Author(s):  
Vangelis Vergetis ◽  
Dimitrios Skaltsas ◽  
Vassilis G Gorgoulis ◽  
Aristotelis Tsirigos
Keyword(s):  
Machine Learning ◽  
Big Data ◽  
Drug Development ◽  
Development Risk

Public Policy Agenda Adapts to Needs

ASHA Leader ◽  
2012 ◽  
Vol 17 (15) ◽  
pp. 23-23
Author(s):  
George Lyons
Keyword(s):  
Public Policy ◽  
Policy Agenda
Sign in / Sign up

Export Citation Format

Share Document